摘要
目的:评价一舒合并基础药物(赛乐特、舒必利、氯硝西泮)治疗抑郁症的临床疗效和副反应。方法:采用基础用药随机对照法,符合中国精神障碍分类与诊断标准第三版(CCMD-3)单次或复发性抑郁发作[1]的104例,随机入组,其中研究组为一舒合并基础药物治疗计53例、对照组为基础药物治疗计51例;住院治疗4周;采用汉密顿焦虑量表(HAMA)和抑郁量表(HAMD)及HAMD总粗分、7因子分、抗抑郁药副反应量表(SERS),评定疗效和副反应[2]。结果:研究组与对照组在治疗1周HAMD量表总粗分、焦虑/躯体化、日夜变化、绝望感均P<0.001;治疗4周末总体疗效相近,而研究组在总粗分、焦虑/躯体化、认识障碍减分率偏高。副反应主要为便秘、口干、躯体疲倦、嗜睡,而无显著消化道反应。结论:一舒合并赛乐特治疗抑郁症起效快、依从性好,只要对便秘、口干、无力等副反应进行对症处理并不影响治疗。
Objectives:To investigate the clinical efficacy and side effects of the united treatment with buspirone and the basic medicine(paroxetine,sulpiride and clonazepam)for depression.Methods: 104 cases of patients with depression,coincident with CCMD - 3,were divided into two groups randomly and treated f or four weeks,the observed group(53 cases)was treated with buspirone and the basic medicine,while the control group(51 cases)was only treated with the basic medicine.The clinical efficacy and side effects were assessed with Hamilton Anxiety scale(HAMA) .Hamilton Depression scale(HAMD) ,HAMD total score,seven factors score and Rating Scale for Side Effects( SERS) . Results: After one-week treatment, there were significant differences between the two groups in HAMD total score, anxiety /somatization, variation between day and night, and feeling of despair (P <0.001) .There was no significant difference in overall efficacy, while the improvement in HAMD total score, anxiety/somatization and cognitive disturbance was more obvious in the observed group, in which the main side effects were constipation, dry mouth, tiredness and drowsiness and there was no significant digestive tract discomfort. Conclusions: There are fast efficacy and good compliance in depression patients treated with buspirone unitd with paroxetine. If managed in time, the side effects such as constipation,dry mouth and tiredness do not affect the treatment.
出处
《中国民康医学》
2003年第12期719-721,共3页
Medical Journal of Chinese People’s Health
